Cytotoxic chemotherapy is associated with damage to a number of proliferating cell populations, notably the bone marrow, gut epithelium and the gonads. In clinical settings, the recovery time of marrow and gut are dose limiting; however, at the 'tolerable' dose for these acute effects, irreparable damage may be done to testicular and ovarian function. Thus, numerous reports suggest that permanent infertility may accompany curative drug therapy for neoplasia, especially Hodgkin's disease (Sherins & DeVita, 1973; Schilsky et al., 1980; Rivkees & Crawford, 1988) .
In adult males, the incidence of permanently induced azoospermia from combination chemotherapy with six or more courses of nitrogen mustard, vincristine or vinblastine, procarbazine, and prednisone (MOPP or MVPP) is 80-90% (Schilsky et al., 1980) . Testicular function in prepubertal males may be partially protected from cytotoxic drugs, as evidenced by more normal gonadotropin levels and usually normal progression through puberty (Rivkees & Crawford, 1988; Sherins et al., 1978) .
The possibility that endocrine manipulations can alter these clinical changes remains unanswered. In females, there appears to be a marked age-related increase in sensitivity to ovarian damage (Shilsky et al., 1981; Chapman et al., 1979) . Preservation of ovarian follicles through the use of oral contraceptives has been suggested although the influence of age on sensitivity has not been carefully addressed (Chapman & Sutcliffe, 1981; King et al., 1985) . In the rat, administration of a gonadotropin releasing hormone analogue has been shown to protect partially against follicular damage induced by cyclophosphamide (Ataya et al., 1985) .
In males, less is known about the possibility for testicular protection through endocrine manipulations. In rats, recovery from nitrofuran toxicity is hastened by pretreatment with testosterone or oestradiol (Nelson et al., 1954) . In preliminary experiments, we demonstrated partial testicular protection in mice from very toxic (>LD50) doses of cyclophosphamide, but we and others were unable to produce permanent infertility or demonstrate consistent protection with this model (Glode et al., 1981 (Glode et al., , 1982 da Cunha et al., 1987) .
The aim of the present study was to explore the possibility that endocrine manipulation might be protective in the rat model for 'permanent' infertility which we developed (Gould et al., 1983) . The rationale for these investigations was the hypothesis that reduction in gonadotropin stimulation of testicular Leydig cells and germinal epithelium might induce a lower proliferative rate in the germinal epithelium and thereby reduce the effects of procarbazine, which is most active against proliferating cells.
Intact male Wistar rats were treated with a number of different protocols designed to suppress spermatogenesis as shown in Table I . Serum LH and testosterone levels were measured as reported (Niswender et al., 1968; Berndtson et al., 1974 (Figure 1 ).
Based on these findings, we treated a second group of animals with testosterone and oestradiol implants for 4 weeks followed by weekly procarbazine injections for 10 weeks. Control animals received only the procarbazine injections. Some animals were killed during the experiment for histological examination; at the end of the experimental period, the implants were removed from the experimental group and both groups were allowed to recover for 12 weeks. All remaining animals were then killed and testes and epididymides were processed for histology. Figure 2 shows the effects of chronic procarbazine administration in an unprotected rat immediately after the 12 week recovery period. Residual tubules are shrunken and contain few if any germ cells, and Sertoli cells are vacuolated. In contrast, animals protected by testosterone plus oestradiol implants had a more orderly appearance of the germinal layer along with Sertoli cell nuclei ( Figure 3 ).
We quantified recovery at 12 weeks in the two groups of animals by counting round cross-sectional tubules in random fields from throughout the length of the testes. Two blinded observers scored each of approximately 100 tubules as positive or negative for spermatogenesis and their scores were added to produce the data in Table II . In addition, the observers noted the presence or absence of sperm in the epididymis on the same sections. It can be seen that in three of the five animals, recovery was sufficient to produce mature sperm and companion groups of animals similarly treated were fertile. However, the presence of minimal spermatogenesis in the control animals also indicated that some of these animals were destined to recover and such recovery was proved by fertility in prolonged observation of similarly treated animals (data not shown).
We feel the studies reported here demonstrate several important features of experiments designed to test the 'suppression/protection' hypothesis we put forward several years ago. First, they show that protection can indeed be achieved in the rat/procarbazine model as we had hoped minal aplasia and tubule mineralization most prominent at the caudal pole of the testis. Such damage was not seen in animals which received steroidal suppression, while those which received both steroids and D-Leu6-GnRH showed worse damage. This section was taken from an animal which had been allowed to recover for 18 weeks. Bar=60p1M. Figure 2 Effects of chronic procarbazine administration on the rat testis. This section was taken from a rat which received 10 weekly intraperitoneal injections of 200 mg kg-' procarbazine freshly dissolved in 0.5 ml normal saline followed by a 12 week recovery period. Figure 3 Recovery from procarbazine administration in a rat protected by testosterone and oestradiol implants. This animal received a 2.5 cm testosterone and a 0.5 cm oestradiol polydimethysiloxane implant (Stratton & Ewing, 1973) for 4 weeks prior to the initiation of procarbazine treatment as in Figure 2 . Tubules with normal return of spermatogenesis are easily found among those still displaying no spermatogenesis. These findings were quantitated in Table II . Bar = 60 gM. (Gould et al., 1983) . Delic et al. (1986 Delic et al. ( , 1987 have also shown that testicular protection can be achieved in this model using testosterone pretreatment for sufficient time. A direct comparison of their data with our own in animals pretreated for four weeks suggests that testosterone plus oestradiol suppression may result in more complete protection than testosterone alone (we observed approximately 20% tubular recovery 12 weeks after treatment with five times the total procarbazine dose they used compared to approximately 5% recovery seen in their animals after 8 weeks of recovery). While such comparisons are difficult, they point out the importance of more completely understanding the mechanisms and potential methods of protection.
A second factor in our data which bears emphasis is the histological damage induced by D-Leu6-GnRH injections in the rat. In contrast to the findings of Rivier et al. (1979) , we noted greater permanent toxicity from GnRH analogue treatment in rats, an effect that has also been reported by others (Lefebvre et al., 1984) . Pogach et al. (1988) noted partial protection of spermatogenesis in procarbazine treated rats only if testosterone was co-administered with a GnRh antagonist, while Karashima et al. (1988) achieved protection using a GnRH agonist alone.
Other species and different GnRH analogues have given conflicting results as well. Potentiation of the gonadal toxicity of cyclophosphamide in a dog model has been reported Individual animals received 10 intraperitoneal injections of 200 mg kg-' procarbazine hydrochloride (a gift from Roche Laboratories, Nutley, NJ) in 0.5 ml normal saline. T + E protected animals were implanted with PDS tubing 602-305 (Dow Corning, Midland, MI) and Silastic Medical Adhesive A (Dow Corning) containing testosterone (T, 2.5 cm) or oestradiol-17,3 (E, 0.5 cm) (purchased from Sigma, St Louis, MO) 4 weeks prior to beginning procarbazine injections. The control animal received saline injections and no implants. At the end of the procarbazine injections, implants were removed and animals were allowed to recover for 12 weeks. After killing by cervical dislocation testes and epididymides were removed in pairs, weighed, and fixed in Bouins fluid embedded in paraffin, and sectioned at 6 SAM, then stained with haematoxylin and eosin. Two blinded observers scored approximately 100 round tubules each from random sections taken throughout the length of the testis for the presence or absence spermatogenesis. Their combined scores are indicated. The averages between the groups are significantly different at the P = 0.01 level by the one-sided Wilcoxon rank sum test.
when the agonist, nafarelin, was co-administered (Goodpasture et al., 1988) while, in the baboon, protection was seen using a D-tryptophan-6 agonist (Lewis et al., 1985) . Attempts to repeat our own experiments in mice have either been negative or inconclusive (Glode et al., 1982; da Cunha et al., 1987) .
In humans, two small trials which attempted to explore the suppression/protection hypothesis have been unsuccessful. In the first, Waxman (1985) used what may have been inappropriately low doses of a GnRH agonist to suppress spermatogenesis during chemotherapy. In the second, Johnson et al. (1985) administered a GnRH agonist for too brief a time to achieve suppression prior to the institution of chemotherapy. This experiment may have been similar to one in rats in which no protective effect of androgens was seen after 4 weeks of suppression while protection increased to a maximum after 6-8 weeks (Delic et al., 1987) .
The present study, therefore, both confirms the potential for suppressing gonadal function to protect from the damaging effects of chemotherapy, while highlighting the difficulties encountered in drawing conclusions from animal models. In truth, there is not an accurate animal model for MOPP induced sterility. We attempted to combine cytotoxic drugs to produce a more accurate model in rats but were unconvinced that combination therapy was more toxic than single agents (Glode et al., 1982) . Given these difficulties, the direction in which such research should proceed is particularly vexing for the clinician. On the one hand, further detailed studies on the mechanisms involved in cytotoxic damage to gonadal stem cells and the companion mechanisms of protection will of necessity need to be done in animals. On the other hand, it would appear that such studies may have rather limited relevance to the human problem.
We believe that only a clinical trial can finally answer the question of whether fertility preservation is possible by suppressing spermatogenesis. Essential features of such a trial would include willingness of patients and investigators to delay the start of cytotoxic chemotherapy for a sufficient period to achieve suppression (an unacceptable condition to many patients and physicians). Moreover, patients would need to be informed that their slim chances for fertility after regimens such as MOPP might actually be reduced rather than enhanced. Sperm banking for trial participants would therefore be recommended, even though its overall success rate is limited. Finally, in the absence of such a trial, young males with Hodgkin's disease who require chemotherapy should be informed of the possibility for treatment with equally effective, yet less toxic (from a gonadal point of view) therapy programs such as ABVD (Viviani et al., 1985) .
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